ライフサイエンスコーパス: hematopoietic cell transplant

1 lood specimens from recipients of allogeneic hematopoietic cell transplant.

2 fe-threatening complication after allogeneic hematopoietic cell transplant.

3 ate nonrelapse mortality after an allogeneic hematopoietic cell transplant.

4 ith morbidity and mortality after allogeneic hematopoietic cell transplant.

5 fferences have not been shown for allogeneic hematopoietic cell transplant.

6 ded HZ prophylaxis for at least 1 year after hematopoietic cell transplant.

7 is the most common indication for allogeneic hematopoietic cell transplant.

8 h IT therapy and consideration of allogeneic hematopoietic cell transplant.

9 of morbidity and mortality after allogeneic hematopoietic cell transplant.

10 s an often lethal complication of allogeneic hematopoietic cell transplant.

11 nized by T cells in recipients of allogeneic hematopoietic cell transplants.

12 esponse to pathogens, tumors, and allogeneic hematopoietic cell transplants.

13 us-tumor effects in recipients of allogeneic hematopoietic cell transplants.

14 as limited the progress of studies involving hematopoietic cell transplants.

15 1A:LLT1 (KLRB1:CLEC2D) interactions in human hematopoietic cell transplants.

16 e successful treatment of blood cancers with hematopoietic cell transplants.

17 cluding the possibility of purged autologous hematopoietic cell transplants.

18 can treat infections complicating allogeneic hematopoietic cell transplants.

19 aspergillosis among recipients of allogeneic hematopoietic-cell transplants.

20 ses zoster and is common among recipients of hematopoietic-cell transplants.

21 of CMV infection in recipients of allogeneic hematopoietic-cell transplants.

22 the incidence of CMV events in recipients of hematopoietic-cell transplants.

23 ere evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-iden

24 Autologous hematopoietic cell transplant (AHCT) for HIV-infected pa

25 Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompr

26 survival in BPDCN, if offered an allogeneic hematopoietic cell transplant (allo-HCT) as consolidativ

27 Allogeneic hematopoietic cell transplant (allo-HCT) can be curative

28 The ability to distinguish allogeneic hematopoietic cell transplant (allo-HCT) recipients at r

29 a significant complication facing allogeneic hematopoietic cell transplant (allo-HCT) recipients, as

30 a significant complication facing allogeneic hematopoietic cell transplant (allo-HCT) recipients, as

31 fection, based on a cohort of 237 allogeneic hematopoietic cell transplant (allo-HCT) recipients, tha

32 use of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients.

33 Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute

34 ortionately affects recipients of allogeneic hematopoietic cell transplant (allo-HCT), and timely det

35 nduce a complete remission before allogeneic hematopoietic cell transplant (alloHCT) is current pract

36 tic cell transplant (autoHCT) and allogeneic hematopoietic cell transplant (alloHCT).

37 In hematopoietic cell transplants, alloreactive T cells med

38 s of allogeneic (Allo) and autologous (Auto) hematopoietic cell transplant and CD19-directed chimeric

39 3 consecutive young males with cALD prior to hematopoietic cell transplant and its association with m

40 roceed to poststudy consolidative allogeneic hematopoietic cell transplant and/or chimeric antigen re

41 gene (TLR9) in a cohort of 336 recipients of hematopoietic-cell transplants and their unrelated donor

42 y immunocompromised diagnosis and history of hematopoietic cell transplant, and among survivors immun

43 rch in the fields of solid organ transplant, hematopoietic cell transplant, and organ donation.

44 tiocytosis, congenital immunodeficiency, and hematopoietic cell transplant are independently associat

45 Patients who receive hematopoietic cell transplants are usually immunosuppres

46 The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric ant

47 yeloid leukemia (AML), as well as autologous hematopoietic cell transplant (autoHCT) and allogeneic h

48 Patients (n = 2802) who received a first hematopoietic cell transplant between 1990 and 2002 were

49 MRD was measured at baseline/preautologous hematopoietic cell transplant (BL/preAutoHCT), premainte

50 Hematopoietic cell transplant candidates and recipients

51 splenectomy, hepatic comorbidity, and higher hematopoietic cell transplant comorbidity index scores.

52 Among patients without hematopoietic cell transplant, congenital immunodeficien

53 Twenty-four hours later, a donor hematopoietic cell transplant consisting of cytokine-mob

54 owed ongoing low-level CMV replication after hematopoietic cell transplant despite receiving letermov

55 The majority of patients in need of a hematopoietic-cell transplant do not have a matched rela

56 der who had undergone their first allogeneic hematopoietic cell transplant during first remission for

57 ce of blood malignancy is the major cause of hematopoietic cell transplant failure.

58 provided a rich basis for improving clinical hematopoietic cell transplants; finding and using protei

59 Research for 1230 subjects receiving a first hematopoietic cell transplant from a human leukocyte ant

60 al history of Crohn's disease was altered by hematopoietic cell transplants from healthy allogeneic d

61 tively analyzed data from 446 patients given hematopoietic cell transplants from HLA-matched related

62 ssential thrombocythemia received allogeneic hematopoietic cell transplants from related (n = 36) or

63 syndrome who received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blo

64 describe a recipient of combined kidney and hematopoietic-cell transplants from an HLA-matched donor

65 in CMV-seropositive recipients of allogeneic hematopoietic-cell transplants from matched related or u

66 tients and 263 matched controls who received hematopoietic-cell transplants from related and unrelate

67 f invasive aspergillosis among recipients of hematopoietic-cell transplants from unrelated donors.

68 diagnosis, whereas 41% were IC without prior hematopoietic cell transplant (HCT) and 9% had prior HCT

69 ease (cGVHD) is a complication of allogeneic hematopoietic cell transplant (HCT) and is associated wi

70 isease remains a formidable challenge to the hematopoietic cell transplant (HCT) and kidney transplan

71 on infectious complications after allogeneic hematopoietic cell transplant (HCT) and may result in si

72 pulmonary complication following allogeneic hematopoietic cell transplant (HCT) and represents a sig

73 Hematopoietic cell transplant (HCT) and solid organ tran

74 cing performed on 732 patients who underwent hematopoietic cell transplant (HCT) between 1989 and 201

75 iagnosed before age 12 months who received a hematopoietic cell transplant (HCT) between July 1982 an

76 Allogeneic hematopoietic cell transplant (HCT) can cure many hemato

77 s obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly uni

78 integrated human herpesvirus 6 (ciHHV-6) in hematopoietic cell transplant (HCT) donors or recipients

79 and bathrooms) on the leukemia (LKM) and the hematopoietic cell transplant (HCT) floors.

80 orafenib maintenance improves outcomes after hematopoietic cell transplant (HCT) for patients with FM

81 eiving intensive chemotherapy and the use of hematopoietic cell transplant (HCT) for specific high-ri

82 all patients who receive an unrelated donor hematopoietic cell transplant (HCT) for the treatment of

83 Only hematopoietic cell transplant (HCT) has been shown to ha

84 n the past 30 days before sample collection, hematopoietic cell transplant (HCT) history, and date of

85 complete remission (CR) prior to allogeneic hematopoietic cell transplant (HCT) is associated with i

86 ratory syncytial virus (RSV) pneumonia after hematopoietic cell transplant (HCT) is associated with s

87 ent of respiratory virus infections prior to hematopoietic cell transplant (HCT) is difficult.

88 ary graft-versus-host disease (cpGVHD) after hematopoietic cell transplant (HCT) manifests as progres

89 nosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) may, in contrast, in

90 d on the Y chromosome (HY-Abs) develop after hematopoietic cell transplant (HCT) of male recipients w

91 Hematopoietic cell transplant (HCT) or chimeric antigen

92 ) or myelodysplasia (MDS), and in allogeneic hematopoietic cell transplant (HCT) recipients (early, u

93 Sepsis disproportionately affects allogeneic hematopoietic cell transplant (HCT) recipients and is ch

94 Adult hematopoietic cell transplant (HCT) recipients are at hi

95 Pediatric hematopoietic cell transplant (HCT) recipients are at hi

96 Hematopoietic cell transplant (HCT) recipients are frequ

97 rgies among solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients are limit

98 guidelines recommend vaccinating allogeneic hematopoietic cell transplant (HCT) recipients at 3 mont

99 guidelines recommend vaccinating allogeneic hematopoietic cell transplant (HCT) recipients at 3 mont

100 Records of solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients at a sing

101 and preventing disseminated viral disease in hematopoietic cell transplant (HCT) recipients but does

102 Cytomegalovirus (CMV) infections in hematopoietic cell transplant (HCT) recipients cause sub

103 irus (CMV) pp65-specific T cells can protect hematopoietic cell transplant (HCT) recipients from CMV

104 Cytomegalovirus (CMV)-seropositive (R+) hematopoietic cell transplant (HCT) recipients have a su

105 chromosomally integrated HHV-6 (iciHHV-6) in hematopoietic cell transplant (HCT) recipients is unclea

106 solized RBV, we aimed to compare outcomes of hematopoietic cell transplant (HCT) recipients treated w

107 of secondary solid cancers among allogeneic hematopoietic cell transplant (HCT) recipients who recei

108 sample types, including (i) whole blood from hematopoietic cell transplant (HCT) recipients with and

109 We retrospectively tested plasma from hematopoietic cell transplant (HCT) recipients with pulm

110 piratory samples and detection in serum from hematopoietic cell transplant (HCT) recipients with resp

111 associated with substantial morbidity among hematopoietic cell transplant (HCT) recipients, but the

112 Neutropenic fever (NF) occurs in >70% of hematopoietic cell transplant (HCT) recipients, without

113 ma viremia with hemorrhagic cystitis (HC) in hematopoietic cell transplant (HCT) recipients.

114 icant cause of morbidity and mortality among hematopoietic cell transplant (HCT) recipients.

115 acute respiratory syndrome coronavirus 2 in hematopoietic cell transplant (HCT) recipients.

116 microangiopathy (TA-TMA) in adult allogeneic hematopoietic cell transplant (HCT) recipients.

117 nza vaccine (SD-QIV) in pediatric allogeneic hematopoietic cell transplant (HCT) recipients.

118 sk patients with hematologic malignancies or hematopoietic cell transplant (HCT) recipients.

119 rding the impact of human bocavirus (BoV) in hematopoietic cell transplant (HCT) recipients.

120 is associated with significant mortality in hematopoietic cell transplant (HCT) recipients.

121 virus (RSV) treatment trials are lacking for hematopoietic cell transplant (HCT) recipients.

122 V) infection causes significant morbidity in hematopoietic cell transplant (HCT) recipients.

123 an cause severe respiratory disease in adult hematopoietic cell transplant (HCT) recipients.

124 (LRD) is a life-threatening complication in hematopoietic cell transplant (HCT) recipients.

125 e serious disease than seasonal influenza in hematopoietic cell transplant (HCT) recipients.

126 ectious pulmonary complication of allogeneic hematopoietic cell transplant (HCT) that is often diagno

127 ients with relapsed CLL following allogeneic hematopoietic cell transplant (HCT) who subsequently rec

128 He underwent hematopoietic cell transplant (HCT) with autologous CD34

129 those with multiple myeloma (MM) undergoing hematopoietic cell transplant (HCT), a population at hig

130 t (SOT) survivors who subsequently require a hematopoietic cell transplant (HCT), although there are

131 ts include enzyme replacement therapy (ERT), hematopoietic cell transplant (HCT), and gene therapy (G

132 s-host disease (aGVHD) after unrelated-donor hematopoietic cell transplant (HCT), leading to US Food

133 Because of advances in hematopoietic cell transplant (HCT), meeting the long-te

134 r cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in partic

135 elapse mortality (NRM) after unrelated donor hematopoietic cell transplant (HCT).

136 ty (CMV-CMI) prevents CMV reactivation after hematopoietic cell transplant (HCT).

137 its acceptance as a pulmonary pathogen after hematopoietic cell transplant (HCT).

138 or cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT).

139 ng antibiotic therapy for patients receiving hematopoietic cell transplant (HCT).

140 Seq) test for diagnosing pulmonary IMI after hematopoietic cell transplant (HCT).

141 y 1 year after ex vivo T-cell-depleted (TCD) hematopoietic cell transplant (HCT).

142 h mortality in ex vivo T-cell depleted (TCD) hematopoietic cell transplant (HCT).

143 ts with hematologic malignancy or undergoing hematopoietic cell transplant (HCT).

144 ogic malignancies (HMs) and in recipients of hematopoietic cell transplant (HCT).

145 a population of consecutive recipients of a hematopoietic cell transplant (HCT).

146 gested a role in enhancing engraftment after hematopoietic cell transplant (HCT).

147 n (IFI) is a serious threat after allogeneic hematopoietic cell transplant (HCT).

148 In adult recipients of allogeneic hematopoietic cell transplants (HCT) studied at 1 year a

149 and its complications in adult patients with hematopoietic cell transplants (HCT), cancer (hematologi

150 ociated complications in adult patients with hematopoietic cell transplants (HCT), cancer, human immu

151 ng (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the t

152 0% to 70% of patients who receive allogeneic hematopoietic cell transplants (HCTs), and the skin is t

153 agement decisions could reduce the number of hematopoietic cell transplants in patients with AML by 2

154 l infection within 100 days after allogeneic hematopoietic cell transplant increases risk of pulmonar

155 ell cycle progression, and survival of human hematopoietic cells transplanted into nonobese diabetic

156 st disease (GVHD) occurring after allogeneic hematopoietic cell transplant is an allo-reactive T cell

157 Among patients with prior hematopoietic cell transplant, liquid malignancy (adjust

158 ns to map sites of hematopoiesis and develop hematopoietic cell transplant methodology.

159 a single-center study of patients undergoing hematopoietic cell transplant (n = 119), the fecal micro

160 ation was present in unrelated recipients of hematopoietic-cell transplants (odds ratio, 5.00; 95% CI

161 Additionally, patients are now referred for hematopoietic cell transplant on a more rational basis.

162 Participants were excluded if they received hematopoietic cell transplant or had relapsed leukemia.

163 med a retrospective review of 738 allogeneic hematopoietic cell transplant patients enrolled from 200

164 We sequenced RV complete genomes from 12 hematopoietic cell transplant patients with infection fo

165 reactivation on lymphocyte reconstitution in hematopoietic cell transplant patients.

166 In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood cells m

167 fferences in approaches, reflecting distinct hematopoietic cell transplant practices, such as ex vivo

168 stic leukemia (AML) who underwent autologous hematopoietic-cell transplant procedures at Stanford Uni

169 In recipients of allogeneic hematopoietic cell transplant, prophylactic management s

170 Allogeneic hematopoietic cell transplant recipients (allo-HCTRs) wi

171 se of infectious complications in allogeneic hematopoietic cell transplant recipients (alloHCT).

172 re collected within 1 day of each other from hematopoietic cell transplant recipients and patients wi

173 In a double-blind controlled trial, 77 hematopoietic cell transplant recipients at risk for VZV

174 It is widely used in hematopoietic cell transplant recipients but is infreque

175 r than 12 months may be beneficial for those hematopoietic cell transplant recipients on continued im

176 hylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initia

177 yelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly a

178 us (VZV) disease occurs in 30% of allogeneic hematopoietic cell transplant recipients who had a histo

179 od (viremia) was detected in 9 of 79 (11.4%) hematopoietic cell transplant recipients with influenza,

180 dex (GMI) values and mortality in allogeneic hematopoietic cell transplant recipients with invasive p

181 sed risk of cutaneous malignant neoplasms in hematopoietic cell transplant recipients, this populatio

182 t clinically significant viral infections in hematopoietic cell transplant recipients.

183 ains a major complication in solid organ and hematopoietic cell transplant recipients.

184 cute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.

185 treatment of CMV pneumonia in recipients of hematopoietic cell transplant remains a significant chal

186 For autologous hematopoietic cell transplant, several studies suggest a

187 kemia in first remission prior to allogeneic hematopoietic cell transplant, the persistence of FLT3 i

188 In survivors who had a recurrence and/or hematopoietic cell transplant, the risk of a grade 3-5 c

189 irst-episode cytomegalovirus infection after hematopoietic cell transplant, the treatment response ra

190 totoxic chemotherapy regimens and allogeneic hematopoietic cell transplant to achieve the best long-t

191 idney transplants in 3 medical centers using hematopoietic cell transplants to establish mixed or com

192 patients scheduled to receive an allogeneic hematopoietic cell transplant were randomized with their

193 Syngeneic and congenic hematopoietic cell transplants were also performed to di

194 he only potential cure for CLL is allogeneic hematopoietic cell transplant, which remains an option a

195 ly 30% of patients who require an allogeneic hematopoietic cell transplant will have an HLA-matched s